Trial Information
Current as of January 14, 2025
Terminated
Keywords
ClinConnect Summary
Single center observational study of the pediatric patient population (\< 18yrs) with normal coagulation function to determine the reference range interval for the clotting parameters reported by the Quantra QPlus system.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \<18yrs
- • Scheduled for procedure requiring anesthesia
- • Access to blood sampling
- • Consented
- Exclusion Criteria:
- • \>18yrs of age
- • pre-term babies
- • patients with know hematological disorders
- • Difficult to obtain blood sampling
- • Has received a blood product transfusion within the last 24hrs.
- • Legal guardian unwilling to consent
Trial Officials
Christopher Tirotta, MD
Principal Investigator
Nicklaus Childrens
About Hemosonics Llc
Hemosonics LLC is a pioneering biotechnology company focused on advancing diagnostic solutions for the management of bleeding and clotting disorders. With a commitment to innovation, Hemosonics develops cutting-edge technologies that enable rapid and accurate assessment of hemostasis, empowering healthcare professionals to make informed clinical decisions. Through rigorous clinical trials and research initiatives, Hemosonics aims to enhance patient outcomes and improve the standard of care in critical care settings. The company is dedicated to fostering partnerships within the medical community to drive advancements in patient diagnostics and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials